At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NBTX NANOBIOTIX SPON ADS EACH REP 1 ORD SHS
Market Closed 12-12 16:00:00 EST
22.70
-0.54
-2.32%
盘后22.70
+0.000.00%
16:04 EST
High23.28Low22.51Vol29.39K
Open23.28D1 Closing23.24Amplitude3.31%
Mkt Cap1.09BTradable Cap566.08MTotal Shares48.24M
T/O675.23KT/O Rate0.12%Tradable Shares24.94M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Nanobiotix Sa : Leerink Partners Raises Target Price to $26 From $24
THOMSON REUTERS  ·  11-25
Nanobiotix Sa : Leerink Partners Raises Target Price to $26 From $24
Nanobiotix Reports €20.4M In Cash And Cash Equivalents As Of Sept. 30
Benzinga  ·  11-25
Nanobiotix Reports €20.4M In Cash And Cash Equivalents As Of Sept. 30
Press Release: Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
Dow Jones  ·  11-25
Press Release: Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations
GlobeNewswire  ·  11-14
NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations
NANOBIOTIX to Participate in Jefferies London Healthcare Conference
GlobeNewswire  ·  11-12
NANOBIOTIX to Participate in Jefferies London Healthcare Conference
Press Release: NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
Dow Jones  ·  10-31
Press Release: NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
Top Premarket Decliners
MT Newswires Live  ·  10-27
Top Premarket Decliners
Nanobiotix provides update on JNJ-1900 after Johnson & Johnson transfer
TIPRANKS  ·  10-24
Nanobiotix provides update on JNJ-1900 after Johnson & Johnson transfer
Nanobiotix Up Over 25%, on Track for Record High Close -- Data Talk
Dow Jones  ·  10-08
Nanobiotix Up Over 25%, on Track for Record High Close -- Data Talk
Stock Track | Nanobiotix (NBTX) Soars 5.07% as Jefferies Triples Price Target
Stock Track  ·  10-06
Stock Track | Nanobiotix (NBTX) Soars 5.07% as Jefferies Triples Price Target
Nanobiotix price target raised to EUR 20 from EUR 13 at H.C. Wainwright
TIPRANKS  ·  10-02
Nanobiotix price target raised to EUR 20 from EUR 13 at H.C. Wainwright
Stock Track | Nanobiotix Surges 16% Pre-Market on Promising Phase 1 Results for Esophageal Cancer Treatment
Stock Track  ·  10-02
Stock Track | Nanobiotix Surges 16% Pre-Market on Promising Phase 1 Results for Esophageal Cancer Treatment
Stock Track | Nanobiotix Soars 10.83% on Promising Phase 1 Results for JNJ-1900 in Esophageal Cancer Treatment
Stock Track  ·  10-02
Stock Track | Nanobiotix Soars 10.83% on Promising Phase 1 Results for JNJ-1900 in Esophageal Cancer Treatment
Stock Track | Nanobiotix (NBTX) Surges 6.51% After-Hours Following Bullish Analyst Rating
Stock Track  ·  10-02
Stock Track | Nanobiotix (NBTX) Surges 6.51% After-Hours Following Bullish Analyst Rating
Stock Track | Nanobiotix (NBTX) Surges 6.51% After-Hours Following Leerink Partners' Bullish $24 Price Target
Stock Track  ·  10-02
Stock Track | Nanobiotix (NBTX) Surges 6.51% After-Hours Following Leerink Partners' Bullish $24 Price Target
Nanobiotix presents data from JNJ-1900 dose escalation, expansion study cohorts
TIPRANKS  ·  10-02
Nanobiotix presents data from JNJ-1900 dose escalation, expansion study cohorts
NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
GlobeNewswire  ·  10-02
NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
Leerink Partners Sticks to Its Buy Rating for Nanobiotix (NBTX)
TIPRANKS  ·  10-01
Leerink Partners Sticks to Its Buy Rating for Nanobiotix (NBTX)
Nanobiotix H1 EPS $(0.12) Up From $(0.50) YoY, Sales $30.202M Up From $10.001M YoY
Benzinga  ·  10-01
Nanobiotix H1 EPS $(0.12) Up From $(0.50) YoY, Sales $30.202M Up From $10.001M YoY
Press Release: NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
Dow Jones  ·  10-01
Press Release: NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results

Introduction

Company Name.
NANOBIOTIX SPON ADS EACH REP 1 ORD SHS
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
Issue price:
--